3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Basal Ganglia Diseases in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (66.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asenbaum, S; Kovacs, GG; Perju-Dumbrava, L; Pirker, S; Pirker, W; Traub-Weidinger, T | 1 |
| Awad, AG; Voruganti, LP | 1 |
| Bartenstein, P; Lerch, H; Masur, H; Oberwittler, C; Saur, HB; Schober, O | 1 |
| Böck, JC; Cordes, M; David, I; Hierholzer, J; Horowski, R; Poewe, W; Sander, B; Schelosky, L | 1 |
| Castelli, L; Cordes, M; Felix, R; Hierholzer, J; Poewe, W; Schelosky, L | 1 |
| Heinz, A; Knable, MB; Raedler, T; Weinberger, DR | 1 |
| Bockisch, A; Hahn, K; Hiemke, C; Nickel, O; Rao, ML; Schlegel, S; Schlösser, R | 1 |
| Dähne, I; Dresel, S; Hahn, K; Mager, T; Scherer, J; Tatsch, K | 1 |
| Biersack, HJ; Broich, K; Grünwald, F; Kasper, S; Klemm, E; Möller, HJ | 1 |
| Dresel, S; Hahn, K; Mager, T; Meisenzahl, E; Möller, HJ; Rossmüller, B; Tatsch, K | 1 |
| Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D | 1 |
| Dresel, S; Frodl, T; Hahn, K; Mager, T; Meisenzahl, EM; Möller, HJ; Preuss, UW; Rossmüller, B; Schmitt, GJ; Tatsch, K | 1 |
1 review(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Basal Ganglia Diseases
| Article | Year |
|---|---|
Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Cognition Disorders; Contrast Media; Cross-Sectional Studies; Dopamine; Follow-Up Studies; Humans; Motivation; Nucleus Accumbens; Parkinsonian Disorders; Pyrrolidines; Schizophrenia; Time Factors; Tomography, Emission-Computed | 2004 |
3 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Basal Ganglia Diseases
| Article | Year |
|---|---|
[Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
Topics: Adult; Aged; Basal Ganglia; Basal Ganglia Diseases; Benzamides; Brain; Cerebellum; Cerebrovascular Circulation; Dopamine Antagonists; Frontal Lobe; Humans; Huntington Disease; Iodine Radioisotopes; Middle Aged; Organotechnetium Compounds; Oximes; Parkinson Disease; Parkinson Disease, Secondary; Pyrrolidines; Receptors, Dopamine D2; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon | 1994 |
D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Clozapine; Dose-Response Relationship, Drug; Female; Frontal Lobe; Humans; Male; Neostriatum; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Brain; Brain Chemistry; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic Disorders; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 2000 |
8 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Basal Ganglia Diseases
| Article | Year |
|---|---|
Dopamine D2 receptor SPECT in corticobasal syndrome and autopsy-confirmed corticobasal degeneration.
Topics: Aged; Autopsy; Basal Ganglia Diseases; Benzamides; Dopamine Antagonists; Female; Humans; Male; Middle Aged; Neurodegenerative Diseases; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Retrospective Studies; Syndrome; Tomography, Emission-Computed, Single-Photon | 2013 |
[The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test].
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Contrast Media; Diagnosis, Differential; Dopamine D2 Receptor Antagonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Time Factors; Tomography, Emission-Computed, Single-Photon | 1993 |
[Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs].
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Brain; Contrast Media; Dopamine Agonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinson Disease; Pyrrolidines; Tomography, Emission-Computed, Single-Photon | 1996 |
Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Brain Mapping; Dopamine Antagonists; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Tomography, Emission-Computed, Single-Photon | 1997 |
[123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benperidol; Benzamides; Bipolar Disorder; Brain; Clozapine; Corpus Striatum; Depressive Disorder, Major; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Frontal Lobe; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia, Paranoid; Tomography, Emission-Computed, Single-Photon | 1997 |
Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Clozapine; Contrast Media; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Iodine Radioisotopes; Male; Middle Aged; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Case-Control Studies; Corpus Striatum; Dopamine Antagonists; Female; Humans; Iodine Radioisotopes; Male; Olanzapine; Pirenzepine; Psychotic Disorders; Pyrrolidines; Receptors, Dopamine; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1999 |
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Corpus Striatum; Female; Health Status; Humans; Iodine Radioisotopes; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon | 2000 |